search for: jennison

Dear all, I'm excited to announce that a new version of gsDesign (3.6.0) is now on CRAN (https://cran.r-project.org/package=gsDesign). gsDesign supports group sequential clinical trial design, largely as presented in Jennison and Turnbull (2000). The 3.6.0 update introduces some significant new features and enhancements: - New gsSurvCalendar() function to enable group sequential design for time-to-event outcomes using calendar timing of interim analysis specification. - toInteger() and print.gsSurv() improvements for...

Dear all, I'm excited to announce that a new version of gsDesign (3.6.0) is now on CRAN (https://cran.r-project.org/package=gsDesign). gsDesign supports group sequential clinical trial design, largely as presented in Jennison and Turnbull (2000). The 3.6.0 update introduces some significant new features and enhancements: - New gsSurvCalendar() function to enable group sequential design for time-to-event outcomes using calendar timing of interim analysis specification. - toInteger() and print.gsSurv() improvements for...

Dear List, I recently asked about any R implementations of Whitehead's methods for sequential clinical trials. Here's the summary of answers so far : 1) There is no R public implementation of those methods 2) There exists an interest for such a package, which does things quite different from Lan-deMets paradigm (shortly : Whitehead's methods allows for unplanned interim analyses

Hello everyone, I need to do a sample size calculation. The study two arms and two endpoints. The two arms are two different cancer drugs and the two endpoints reflect efficacy (based on progression free survival) and toxicity. Until now, I have been trying to understand this in terms of a one-arm design, where the acceptable rate of efficacy might be 0.40, the unacceptable rate of efficacy